CH620430A5 - - Google Patents
Download PDFInfo
- Publication number
- CH620430A5 CH620430A5 CH650277A CH650277A CH620430A5 CH 620430 A5 CH620430 A5 CH 620430A5 CH 650277 A CH650277 A CH 650277A CH 650277 A CH650277 A CH 650277A CH 620430 A5 CH620430 A5 CH 620430A5
- Authority
- CH
- Switzerland
- Prior art keywords
- compound
- titanium
- aluminum
- derivatives
- acetyltryptophan
- Prior art date
Links
- 238000000034 method Methods 0.000 claims description 14
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical class C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 claims description 10
- JUBRTJHDNBZSGI-ONFJWZKWSA-K aluminum (2S)-2-acetamido-3-(1H-indol-3-yl)propanoate Chemical compound [Al+3].C1=CC=C2C(C[C@H](NC(=O)C)C([O-])=O)=CNC2=C1.C1=CC=C2C(C[C@H](NC(=O)C)C([O-])=O)=CNC2=C1.C1=CC=C2C(C[C@H](NC(=O)C)C([O-])=O)=CNC2=C1 JUBRTJHDNBZSGI-ONFJWZKWSA-K 0.000 claims description 10
- 239000010936 titanium Substances 0.000 claims description 9
- DZTHIGRZJZPRDV-UHFFFAOYSA-N Nalpha-Acetyltryptophan Natural products C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 claims description 7
- 229910052782 aluminium Inorganic materials 0.000 claims description 7
- 229940116191 n-acetyltryptophan Drugs 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 6
- 229910052719 titanium Inorganic materials 0.000 claims description 6
- BWFLJEBZOQUCJP-HELSCWPJSA-J [Ti+4].C1=CC=C2C(C[C@H](NC(=O)C)C([O-])=O)=CNC2=C1.C1=CC=C2C(C[C@H](NC(=O)C)C([O-])=O)=CNC2=C1.C1=CC=C2C(C[C@H](NC(=O)C)C([O-])=O)=CNC2=C1.C1=CC=C2C(C[C@H](NC(=O)C)C([O-])=O)=CNC2=C1 Chemical compound [Ti+4].C1=CC=C2C(C[C@H](NC(=O)C)C([O-])=O)=CNC2=C1.C1=CC=C2C(C[C@H](NC(=O)C)C([O-])=O)=CNC2=C1.C1=CC=C2C(C[C@H](NC(=O)C)C([O-])=O)=CNC2=C1.C1=CC=C2C(C[C@H](NC(=O)C)C([O-])=O)=CNC2=C1 BWFLJEBZOQUCJP-HELSCWPJSA-J 0.000 claims description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052797 bismuth Inorganic materials 0.000 claims description 3
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical group [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- DCKVFVYPWDKYDN-UHFFFAOYSA-L oxygen(2-);titanium(4+);sulfate Chemical compound [O-2].[Ti+4].[O-]S([O-])(=O)=O DCKVFVYPWDKYDN-UHFFFAOYSA-L 0.000 claims description 2
- 229910000348 titanium sulfate Inorganic materials 0.000 claims description 2
- JGDITNMASUZKPW-UHFFFAOYSA-K aluminium trichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Al](Cl)Cl JGDITNMASUZKPW-UHFFFAOYSA-K 0.000 claims 1
- 229940009861 aluminum chloride hexahydrate Drugs 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 description 24
- 229940126062 Compound A Drugs 0.000 description 23
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 23
- 231100000397 ulcer Toxicity 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 19
- 230000000694 effects Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000005995 Aluminium silicate Substances 0.000 description 10
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 10
- 235000012211 aluminium silicate Nutrition 0.000 description 10
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 7
- 208000013403 hyperactivity Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 206010020843 Hyperthermia Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000000767 anti-ulcer Effects 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 4
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 4
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 4
- 241000978776 Senegalia senegal Species 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 244000144993 groups of animals Species 0.000 description 4
- 230000036031 hyperthermia Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 4
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 4
- 229960003147 reserpine Drugs 0.000 description 4
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- 206010042220 Stress ulcer Diseases 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 208000000718 duodenal ulcer Diseases 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000862 serotonergic effect Effects 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- BKPRVQDIOGQWTG-FKXFVUDVSA-N (1r,2s)-2-phenylcyclopropan-1-amine;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-FKXFVUDVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000002276 neurotropic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 1
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/06—Aluminium compounds
- C07F5/069—Aluminium compounds without C-aluminium linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/003—Compounds containing elements of Groups 4 or 14 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/94—Bismuth compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7616121A FR2352546A1 (fr) | 1976-05-26 | 1976-05-26 | Nouveaux derives, insolubles, du n-acetyl-tryptophane et medicaments a base de ces derives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH620430A5 true CH620430A5 (ko) | 1980-11-28 |
Family
ID=9173718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH650277A CH620430A5 (ko) | 1976-05-26 | 1977-05-26 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4215136A (ko) |
| BE (1) | BE855097A (ko) |
| CA (1) | CA1085409A (ko) |
| CH (1) | CH620430A5 (ko) |
| DE (1) | DE2723903A1 (ko) |
| ES (1) | ES459184A1 (ko) |
| FR (1) | FR2352546A1 (ko) |
| GB (1) | GB1561201A (ko) |
| GR (1) | GR58463B (ko) |
| IT (1) | IT1115336B (ko) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA557705A (en) * | 1958-05-20 | R. Snyder Harold | Preparation of n-acyl-tryptophans | |
| FR51M (ko) * | 1960-06-03 | 1960-11-28 |
-
1976
- 1976-05-26 FR FR7616121A patent/FR2352546A1/fr active Granted
-
1977
- 1977-05-23 US US05/799,532 patent/US4215136A/en not_active Expired - Lifetime
- 1977-05-25 CA CA279,122A patent/CA1085409A/en not_active Expired
- 1977-05-26 GR GR53560A patent/GR58463B/el unknown
- 1977-05-26 DE DE19772723903 patent/DE2723903A1/de not_active Withdrawn
- 1977-05-26 GB GB22228/77A patent/GB1561201A/en not_active Expired
- 1977-05-26 IT IT24051/77A patent/IT1115336B/it active
- 1977-05-26 BE BE177959A patent/BE855097A/xx not_active IP Right Cessation
- 1977-05-26 CH CH650277A patent/CH620430A5/fr not_active IP Right Cessation
- 1977-05-26 ES ES459184A patent/ES459184A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ES459184A1 (es) | 1978-05-01 |
| DE2723903A1 (de) | 1977-12-15 |
| GB1561201A (en) | 1980-02-13 |
| GR58463B (en) | 1977-10-12 |
| FR2352546B1 (ko) | 1978-11-03 |
| CA1085409A (en) | 1980-09-09 |
| IT1115336B (it) | 1986-02-03 |
| US4215136A (en) | 1980-07-29 |
| BE855097A (fr) | 1977-11-28 |
| FR2352546A1 (fr) | 1977-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3231042B2 (ja) | ２−（２，６−ジ−ハロ−フェニルアミノ）フェニル酢酸の誘導体の硝酸エステルおよびその製造法 | |
| LU85248A1 (fr) | Derives de thiazolidine,procede pour leur preparation et compositions pharmaceutiques les contenant | |
| CA2083475C (fr) | Derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant | |
| HU195181B (en) | Process for producing fluorallylamine derivatives | |
| CH655924A5 (fr) | Derives de l'acide 4-phenyl 4-oxo 2-butenoique, leurs sels, leur preparation, medicaments et compositions les renfermant. | |
| JPH0140010B2 (ko) | ||
| CH620430A5 (ko) | ||
| EP0133176A1 (fr) | Composition pharmaceutique ou vétérinaire destinée à combattre des troubles ischémiques cardiaques | |
| LU83713A1 (fr) | Derives de la pyrimidine,leur procede de preparation et les compositions pharmaceutiques les contenant | |
| EP0094283B1 (fr) | Forme médicamenteuse de théophylline à action prolongée | |
| FR2465481A1 (fr) | Compositions anti-ulcereuses a base d'acide 5-methoxy-2-methyl-3-indolyl-acethydroxamique | |
| EP0135510B1 (fr) | Nouveaux medicaments appartenant a la famille des derives d'halo genobenzophenone-oxime | |
| WO1981002295A1 (fr) | Phenoxyisobutyrates de moroxydine et medicaments les contenant | |
| FR2572285A1 (fr) | Medicaments a base de nouveaux derives de la phenethylaminoalcoyle-6 furo-(3,4-c)-pyridine | |
| FR2518537A1 (fr) | Nouveaux derives de l'acide phenylacetique, leur preparation et compositions les contenant | |
| FR2708611A1 (fr) | Sel de codéine de l'acide 2-(3-benzoylphényl)propionique, procédé d'obtention et compositions pharmaceutiques le contenant. | |
| FR2491471A1 (fr) | Benzoxazolinones substituees, leur preparation et leur application en therapeutique | |
| CH622251A5 (ko) | ||
| CH628321A5 (en) | Process for the preparation of derivatives of isobutyramide and medical composition containing these derivatives | |
| CH622023A5 (en) | Process for the preparation of a water-soluble compound based on a substituted phenylaminoalcohol | |
| LU84750A1 (fr) | Nouvelles argiles modifiees,leur procede de preparation et compositions therapeutiques a base de ces argiles | |
| CA1227136A (fr) | Compositions pharmaceutiques contenant a titre de principe actif l'acide 4-(benzofuran-2-yl)4-oxo buten-2-oique et/ou de ses sels pharmaceutiquement acceptables | |
| EP0091528B1 (fr) | Nouvel agent utilisable pour le traitement de certaines formes de la dépression constitué par le N-(1-propyl-2-pyrrolidylméthyl)-2-méthoxy 5-sulfamoyl benzamide | |
| BE844832A (fr) | Nouvelles amidinourees, leur preparation et leur emploi | |
| BE880487A (fr) | Procede de preparation de quinazolines substituees, quinazolines ainsi obtenues et methode de traitement de l'hypertension les utilisant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUE | Assignment |
Owner name: LES LABORATOIRES MERAM |
|
| PL | Patent ceased |